Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
KC Ohaegbulam, A Assal, E Lazar-Molnar… - Trends in molecular …, 2015 - cell.com
The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-
L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition …
L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition …
[HTML][HTML] Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults.
With a median patient survival of less than two years, GBM represents one of the biggest …
With a median patient survival of less than two years, GBM represents one of the biggest …
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Programmed cell death–1 (PD-1) is a coinhibitory receptor that suppresses T cell activation
and is an important cancer immunotherapy target. Upon activation by its ligand PD-L1, PD-1 …
and is an important cancer immunotherapy target. Upon activation by its ligand PD-L1, PD-1 …
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1)
is crucial for the development of reversal strategies. In anti-PD-1-resistant models …
is crucial for the development of reversal strategies. In anti-PD-1-resistant models …
Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer
J He, Y Hu, M Hu, B Li - Scientific reports, 2015 - nature.com
Lung cancer is currently the leading cause of cancer-related death in worldwide, non-small
cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum …
cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum …
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer
M Sznol, L Chen - Clinical cancer research, 2013 - AACR
The immune suppressive molecule programmed death-1 (PD-1) is upregulated in activated
T lymphocytes and inhibits T-cell function upon binding to its ligands B7-H1 (PD-L1, CD274) …
T lymphocytes and inhibits T-cell function upon binding to its ligands B7-H1 (PD-L1, CD274) …
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Y **ao, S Yu, B Zhu, D Bedoret, X Bu… - Journal of Experimental …, 2014 - rupress.org
We report that programmed death ligand 2 (PD-L2), a known ligand of PD-1, also binds to
repulsive guidance molecule b (RGMb), which was originally identified in the nervous …
repulsive guidance molecule b (RGMb), which was originally identified in the nervous …
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities
A dynamic interplay exists between host and tumor, and the ability of the tumor to evade
immune recognition often determines the clinical course of the disease. Significant …
immune recognition often determines the clinical course of the disease. Significant …
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
O Hamid, RD Carvajal - Expert opinion on biological therapy, 2013 - Taylor & Francis
Introduction: Multiple agents targeting the immune “checkpoint” programmed death-1 (PD-1)
pathway have demonstrated early evidence of durable clinical activity and an encouraging …
pathway have demonstrated early evidence of durable clinical activity and an encouraging …
Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
Quantitative systems pharmacology (QSP) modeling is an emerging mechanistic
computational approach that couples drug pharmacokinetics/pharmacodynamics and the …
computational approach that couples drug pharmacokinetics/pharmacodynamics and the …